bioRxivCancer Biology
An integrative systems biology and experimental approach identifies convergence of epithelial plasticity, metabolism, and autophagy to promote chemoresistance
S. Xu, K. E. Ware, Y. Ding, S. Y. Kim, M. Sheth, S. Rao, W. Chan, A. J. Armstrong, W. C. Eward, M. K. Jolly, J. A. Somarelli
Abstract
The evolution of therapeutic resistance is a major cause of death for patients with solid tumors. The development of therapy resistance is shaped by the ecological dynamics within the tumor microenvironment and the selective pressure induced by the host immune system. These ecological and selective forces often lead to evolutionary convergence on one or more pathways or hallmarks that drive progression. These hallmarks are, in turn, intimately linked to each other through gene expression networks. Thus, a deeper understanding of the evolutionary convergences that occur at the gene expression level could reveal vulnerabilities that could be targeted to treat therapy-resistant cancer. To this end, we used a combination of phylogenetic clustering, systems biology analyses, and wet-bench molecular experimentation to identify convergences in gene expression data onto common signaling pathways. We applied these methods to derive new insights about the networks at play during TGF-{beta}-mediated epithelial-mesenchymal transition in a lung cancer model system. Phylogenetics analyses of gene expression data from TGF-{beta} treated cells revealed evolutionary convergence of cells toward amine-metabolic pathways and autophagy during TGF-{beta} treatment. Using high-throughput drug screens, we found that knockdown of the autophagy regulatory, ATG16L1, re-sensitized lung cancer cells to cancer therapies following TGF-{beta}-induced resistance, implicating autophagy as a TGF-{beta}-mediated chemoresistance mechanism. Analysis of publicly-available clinical data sets validated the adverse prognostic importance of ATG16L expression in multiple cancer types including kidney, lung, and colon cancer patients. These analyses reveal the usefulness of combining evolutionary and systems biology methods with experimental validation to illuminate new therapeutic vulnerabilities.
- organism: human
- assay: bulk RNA-seq
- research focus: drug response / drug discovery
- research focus: cell type annotation
- approach: statistical model
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- In vitro model for resistance in oncogene-dependent tumors at the limit of radiological detectability
N. Müller, J. Brägelmann, … J. Berg·bioRxiv·Sep 5, 2019
- Resistance to EGFR inhibitors in lung cancer occurs through horizontal transfer and is associated with increased caveolins expression
S. Junqueira-Neto, A. R. Oliveira, … J. C. Machado·bioRxiv·Feb 20, 2022
- Selection for targeted therapy resistance leads to an indirect selection for higher phenotypic plasticity and enhanced evolvability to orthogonal stressors
Alicia Bjornberg, Xierali Aobuli, … Andriy Marusyk·bioRxiv·Apr 3, 2026
- Cell migration sculpts evolutionary dynamics favouring therapy resistance in lung cancer
Ajay Bhargava, Xiao Fu, … Erik A. Sahai·bioRxiv·Sep 15, 2025
- Autophagy mediates cancer cell resistance to doxorubicin induced by the Programmed Death 1/Programmed Death Ligand 1 immune checkpoint axis
L. Minassian, D. Sanwalka, … C. H. Graham·bioRxiv·Jan 17, 2023
- Understanding the Evolutionary Games in NSCLC Microenvironment
R. Bhattacharya, R. V. Velde, … D. Basanta·bioRxiv·Nov 30, 2020